Company Focuses on Delivery Platform
PHARMA: Halozyme’s Cancer Drug Missed Its Mark in Trials
■ By JARED WHITLOCK
NEWS
For many biotechs, the news would be a death knell.
Halozyme on Nov. 4 reported that its lead drug for pancreatic cancer failed to extend patient lives in latestage clinical trials. The San Diego company said it will lay off 160 people, or about 55%...
Read latest San Diego Business Journal online.
Online newspapers
at PressDisplay.